PBMC ImmunoGraft® Platform

Humanized mouse models with a humanized immune system (HIS) enable in vivo studies with human immune cells and a human tumor in a mouse system.  These types of mouse models are critical for the development of next generation immune-oncology (IO) therapeutics. 

Champions Oncology has developed a peripheral blood mononuclear cell (PBMC) ImmunoGraft® Platform that utilizes a human cell-line derived xenograft (CDX) or patient derived xenograft (PDX) model co-engrafted with human PBMCs in an immunodeficient mouse. This platform can be utilized for studying checkpoint blockade and other human T-cell-directed Immuno-oncology therapies such as bi-specific T-cell engager antibodies.


Champions Oncology’s PBMC ImmunoGraft® Platform